Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2014 Jun;21(3):209-16.
doi: 10.1097/MED.0000000000000057.

Testosterone, aging and survival: biomarker or deficiency

Molly M Shores  1 , Alvin M Matsumoto
Affiliations
Review

Testosterone, aging and survival: biomarker or deficiency

Molly M Shores et al. Curr Opin Endocrinol Diabetes Obes. 2014 Jun.

Abstract

Purpose of review: The purpose of this study is to review recent studies that examined the association of endogenous and exogenous testosterone and mortality in older men.

Recent findings: Over the past several years, there has been a steep rise in testosterone prescriptions. The increased use of testosterone occurred in the context of several studies that reported an association between low serum testosterone and increased cardiovascular events and mortality. In contrast, recent studies have reported an association between testosterone treatment and adverse events. A testosterone treatment trial of mobility-impaired elderly men with prevalent cardiovascular disease was stopped due to increased cardiovascular events in the T-treated men and a meta-analysis reported increased cardiovascular events in T-treated men. In two recent large observational studies, testosterone treatment was associated with an increased risk for serious adverse cardiovascular events.

Summary: Low testosterone is associated with mortality in multiple cohort studies; however, it is unclear if this is a causal association or due to low testosterone being a biomarker of poor health. Given recent reports of adverse outcomes associated with testosterone treatment, a conservative use of testosterone is warranted in men with cardiovascular disease who may be at greater risk for adverse outcomes.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Handelsman DJ. Global trends in testosterone prescribing, 2000–2011: expanding the spectrum of prescription drug misuse. Med J Aust. 2013;199:548–551. - PubMed
    1. Rosenthal E. New York Times. New York: New York Times; 2013. A Push to Sell Testosterone Gels Troubles Doctors. US edition.
    1. Schwartz LM, Woloshin S. Low “T” as in “template”: how to sell disease. JAMA internal medicine. 2013;173:1460–1462. - PubMed
    1. Baillargeon J, Urban RJ, Ottenbacher KJ, et al. Trends in androgen prescribing in the United States, 2001 to 2011. JAMA internal medicine. 2013;173:1465–1466. Discusses increased testosterone prescribing over the past several years by calendar year and age decades. Annual trends in testosterone prescribing in the United states by age. - PMC - PubMed
    1. Muraleedharan V, Marsh H, Kapoor D, et al. Testosterone deficiency is associated with increased risk of mortality and testosterone replacement improves survival in men with type 2 diabetes. Eur J Endocrinol. 2013;169:725–733. - PubMed

Publication types